Migalastat (1‐deoxygalactonojirimycin), an active site‐directed imino sugar reversible inhibitor of alpha‐galactosidase A, was shown to paradoxically rescue the activity and the stability of this enzyme in cells from Fabry disease patients, opening the way to further development of this approach (Fan et al, 1999). This evidence concerns the gene GLA and Fabry disease.